Black Rock Inc. Allogene Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 16,445,682 shares of ALLO stock, worth $49.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,445,682
Previous 9,652,930
70.37%
Holding current value
$49.3 Million
Previous $43.1 Million
11.19%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ALLO
# of Institutions
173Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$56.1 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$24.6 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$23 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$20.7 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.79MShares$17.4 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $431M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...